SCHEMBL4721735

SCHEMBL4721735

COc1cccc(NC(=O)Nc2ncc(-c3cc(C(=O)O)c4cn[nH]c4n3)s2)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.51
AURKA O14965 2/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MITF O75030 1/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
MAPT P10636 2/20 0.44
DYRK1A Q13627 1/20 0.44
GRIK1 P39086 1/20 0.43
CYP1A2 P05177 1/20 0.43
CSNK2A2 P19784 3/20 0.43
CSNK2A1 P68400 3/20 0.43
PAX8 Q06710 1/20 0.43
CDK8 P49336 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724126 0.88 CNR1 (0.47) FLT3AURKANPC1RAB9AMEN1
SCHEMBL4721455 0.87 MEN1 (0.48) FLT3AURKANPC1RAB9AMEN1
SCHEMBL4824159 0.85 CSNK2A2 (0.44) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL4724487 0.85 NPC1 (0.45) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL4764295 0.84 BLM (0.44) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL4721629 0.84 FLT3 (0.49) FLT3RAB9AMEN1KMT2ATP53
SCHEMBL4765909 0.82 TRPV1 (0.45) FLT3
SCHEMBL4724468 0.82 MAPT (0.46) AURKANPC1RAB9AMEN1KMT2A
SCHEMBL4723103 0.82 CNR1 (0.55) FLT3AURKARAB9AMEN1KMT2A
SCHEMBL1323860 0.82 SMYD2 (0.52) NPC1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1912988-B1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA SA (FR) 2014-04-16 EP claimed
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof AVENTIS PHARMA S.A. (FR) 2008-07-31 US claimed
EP-1912988-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF Aventis Pharma S.A. (FR) 2008-04-23 EP claimed
WO-2007017577-A1 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2007-02-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182844-A1 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof PRMT7, PRKACA, PRKX FLT3 525/4885AURKA 273/4885NPC1 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.